Letters
Ethics Genetics
Volume 192 - Issue 2

Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?

Author:  Warwick P Anderson

Med J Aust 2010; 192 (2): 112. || doi: 10.5694/j.1326-5377.2010.tb03441.x
Published online: 18 January 2010
Download PDF (55 KB)
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

To the Editor: The research article by Keogh and colleagues1 on uptake of genetic testing and insurance implications highlights the need to ensure that Australian insurance industry policy in relation to genetic testing does not increase the risk of adverse health outcomes.

The authors called upon the insurance industry and the Human Genetics Advisory Committee (HGAC) of the National Health and Medical Research Council (NHMRC) to reconsider the use of genetic information in relation to insurance.1 Another recently published study has also raised concerns about the way genetic information is used in the insurance industry.2

The HGAC has had initial discussions with the insurance industry about:

Through the HGAC, the NHMRC will encourage the development of an evidence-based process for assessment of genetic tests for use by the insurance industry, to ensure that it meets the required standard for underwriting. This will, in turn, support appropriate, equitable consumer access to optimal health care.

View this article on Wiley Online Library